A BREAKTHROUGH TREATMENT FOR MORE PATIENTS WITH CYSTIC FIBROSIS (CF)1

12+

Triple combination therapy for patients with CF aged 12 years and older, with at least one F508del mutation2

TRIKAFTA is indicated for the treatment of CF in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.